Investment Rating - The report maintains a "Buy" rating for the company, with a target price raised to HKD 496.89 [6][4]. Core Insights - The company is leading in the development of IO 2.0 combination therapies, with three ADC assets (DB-1303, DB-1311, and DB-1305) already initiating four global clinical studies in collaboration with BioNTech [2][12]. - The ADCs are designed to explore various cancer types, including lung cancer and breast cancer, showcasing the potential for broad application in oncology [2][21][27]. - The report highlights the safety profile of the ADCs, particularly DB-1305, which has shown low rates of overlapping toxicity and a drug discontinuation rate of only 4.5% in clinical trials [23][24]. Summary by Sections Section 1: Embracing ADC Combination IO2.0 - The company has initiated four clinical studies for its ADCs in collaboration with BioNTech, focusing on the combination of ADCs with PD-L1/VEGF bispecific antibodies [2][12]. - DB-1311 is exploring various lung cancer types, while DB-1303 is targeting different HER2 expression levels in breast cancer [17][21]. - The ADCs are positioned to expand the treatment landscape for multiple cancer types, leveraging the synergistic effects of IO 2.0 [12][14]. Section 2: DB-1419 - A Novel PD-L1 x B7-H3 ADC - DB-1419 is a newly introduced ADC utilizing a unique "2+2" antibody design, showing superior tumor suppression effects in preclinical studies compared to existing B7-H3 ADCs [27][28]. - The ADC is currently undergoing global I/II phase clinical trials, with data expected in 2026 [28]. Section 3: DB-1317 - ADAM9 ADC for Gastrointestinal Tumors - DB-1317 targets ADAM9, which is highly expressed in various gastrointestinal cancers, demonstrating significant therapeutic potential [31][32]. - The ADC's design allows for targeted delivery of cytotoxic agents, enhancing its efficacy against tumors with high ADAM9 expression [31][32]. Section 4: DUPAC Platform and New Mechanisms - The DUPAC platform introduces innovative payloads aimed at overcoming resistance to existing therapies, with DUP5 showing broad anti-tumor activity [35][40]. - DUP5 operates through a unique mechanism that inhibits mRNA translation, allowing it to target both proliferating and non-dividing cancer cells [35][40].
映恩生物-B（09606）：点评报告：ADC联用IO2.0进度领先，新平台峥嵘初露